Merck & Co. (NYSE: MRK) has just posted earnings that may be a relief to many who were worried about recent Vytorin woes affecting 2008 numbers. The company posted EPS of $0.80 for Q4 and consensus estimates out of First Call were $0.74. Merck is also guiding its fiscal 2008 of $3.28 to $3.38 EPS, and estimates are $3.36, yet after items it sees a revised 2008 EPS range of $3.80 to $4.00.
Merck shares closed at $48.00 yesterday, down from recent 52-week highs north of $60 earlier in January before the Vytorin woes came out. Its shares are indicated up 1% pre-market.
As estimates had been coming down in recent days, this guidance for 2008 may be a relief to many that worried the latest issues would sharply bring down earnings projections.
Jon C. Ogg January 30, 2008
“The Next NVIDIA” Could Change Your Life
NVIDIA has returned 250-fold in the past 10 years as artificial intelligence took off.
But if you missed out on NVIDIA’s historic run, your chance to see life-changing profits from AI isn’t over.
The 24/7 Wall Street Analyst who first called NVIDIA’s AI-fueled rise in 2009 just published a brand-new research report named “The Next NVIDIA.”
The report outlines key breakthroughs in AI and the stocks ready to dominate the next wave of growth. The report is absolutely free. Simply enter your email below
By providing your email address, you agree to receive communications from us regarding website updates and other offerings that may be of interest to you.
You have the option to opt-out of these emails at any moment. For more information, please review our Disclaimer and Terms of Use.